Immunotherapy of Hodgkin Lymphoma

被引：0

作者：

Gilardin, Laurent ^{[1
]}

Amorim, Sandy ^{[1
]}

Bernard, Sophie ^{[1
]}

Ravdan, Odonchimeg ^{[1
]}

Thieblemont, Catherine ^{[1
]}

Brice, Pauline ^{[1
]}

机构：

[1] Hop St Louis, AP HP, Serv Oncohematol, Paris, France

来源：

BULLETIN DU CANCER | 2018年 / 105卷

关键词：

Hodgkin Lymphoma; Immune checkpoint inhibitor; Anti-PD-1; Nivolumab; Pembrolizumab; STEM-CELL TRANSPLANTATION; BRENTUXIMAB VEDOTIN; PHASE-II; PD-1; BLOCKADE; NIVOLUMAB; INTERIM; EFFICACY; PEMBROLIZUMAB; MULTICOHORT; MULTICENTER;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Classical Hodgkin lymphoma (HL) is a rare hematological cancer, affecting preferentially young adults. Using a risk-adapted approach, HL has become highly curable (>80 %) with front-line chemotherapy in addition with radiotherapy, despite long term significant toxicity. Some patients are primary refractory or relapse after first-line chemotherapy, requiring high dose chemotherapy with serious side effects. Studies of the microenvironment from HI tissue reveal ineffective inflammatory and immune cell infiltrate surrounding Reed-Sternberg cells, involving the Programmed cell Death 1 (PD-1)/PD-ligand-1 checkpoint pathways. Recently, immune checkpoint inhibitors demonstrated high efficacy for relapsed and refractory patients, with a favorable safety profile but indeterminate long term outcome. Guidelines for nivolumab or pembrolizumab treatment in HI remain to be established.

引用

页码：S50 / S58

页数：9

共 42 条

[11] Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial [J].

Armand, Philippe ;

Engert, Andreas ;

Younes, Anas ;

Fanale, Michelle ;

Santoro, Armando ;

Zinzani, Pier Luigi ;

Timmerman, John M. ;

Collins, Graham P. ;

Ramchandren, Radhakrishnan ;

Cohen, Jonathon B. ;

De Boer, Jan Paul ;

Kuruvilla, John ;

Savage, Kerry J. ;

Trneny, Marek ;

Shipp, Margaret A. ;

Kato, Kazunobu ;

Sumbul, Anne ;

Farsaci, Benedetto ;

Ansell, Stephen M. .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (14) :1428-+

[12] Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure [J].

Armand, Philippe ;

Shipp, Margaret A. ;

Ribrag, Vincent ;

Michot, Jean-Marie ;

Zinzani, Pier Luigi ;

Kuruvilla, John ;

Snyder, Ellen S. ;

Ricart, Alejandro D. ;

Balakumaran, Arun ;

Rose, Shelonitda ;

Moskowitz, Craig H. .

JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (31) :3733-+

[13] Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma [J].

Carey, Christopher D. ;

Gusenleitner, Daniel ;

Lipschitz, Mikel ;

Roemer, Margaretha G. M. ;

Stack, Edward C. ;

Gjini, Evisa ;

Hu, Xihao ;

Redd, Robert ;

Freeman, Gordon J. ;

Neuberg, Donna ;

Hodi, F. Stephen ;

Liu, Xiaole Shirley ;

Shipp, Margaret A. ;

Rodig, Scott J. .

BLOOD, 2017, 130 (22) :2420-2430

[14]

Castello A, 2018, LEUKEMIA LYMPHOMA, P1

[15] Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma [J].

Chen, Robert ;

Zinzani, Pier Luigi ;

Fanale, Michelle A. ;

Armand, Philippe ;

Johnson, Nathalie A. ;

Brice, Pauline ;

Radford, John ;

Ribrag, Vincent ;

Molin, Daniel ;

Vassilakopoulos, Theodoros P. ;

Tomita, Akihiro ;

von Tresckow, Bastian ;

Shipp, Margaret A. ;

Zhang, Yinghua ;

Ricart, Alejandro D. ;

Balakumaran, Arun ;

Moskowitz, Craig H. .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (19) :2125-+

[16] Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma [J].

Chen, Robert ;

Gopal, Ajay K. ;

Smith, Scott E. ;

Ansell, Stephen M. ;

Rosenblatt, Joseph D. ;

Savage, Kerry J. ;

Connors, Joseph M. ;

Engert, Andreas ;

Larsen, Emily K. ;

Huebner, Dirk ;

Fong, Abraham ;

Younes, Anas .

BLOOD, 2016, 128 (12) :1562-1566

[17] Speed bumps on the road to a chemotherapy-free world for lymphoma patients [J].

Cheson, Bruce D. .

BLOOD, 2016, 128 (03) :325-330

[18] Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification [J].

Cheson, Bruce D. ;

Fisher, Richard I. ;

Barrington, Sally F. ;

Cavalli, Franco ;

Schwartz, Lawrence H. ;

Zucca, Emanuele ;

Lister, T. Andrew .

JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (27) :3059-+

[19] Kinetics and nadir of responses to immune checkpoint blockade by anti-PD1 in patients with classical Hodgkin lymphoma [J].

Dercle, Laurent ;

Ammari, Samy ;

Seban, Romain-David ;

Schwartz, Lawrence H. ;

Houot, Roch ;

Labaied, Nizar ;

Mokrane, Fatima-Zohra ;

Lazarovici, Julien ;

Danu, Alina ;

Marabelle, Aurelien ;

Ribrag, Vincent ;

Michot, Jean-Marie .

EUROPEAN JOURNAL OF CANCER, 2018, 91 :136-144

[20] Early interim 2-[18F]Fluoro-2-Deoxy-D-Glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma:: A report from a joint Italian-Danish study [J].

Gallamini, Andrea ;

Hutchings, Martin ;

Rigacci, Luigi ;

Specht, Lena ;

Merli, Francesco ;

Hansen, Mads ;

Patti, Caterina ;

Loft, Annika ;

Di Raimondo, Francesco ;

D'Amore, Francesco ;

Biggi, Alberto ;

Vitolo, Umberto ;

Stelitano, Caterina ;

Sancetta, Rosario ;

Trentin, Livio ;

Luminari, Stefano ;

Iannitto, Emilio ;

Viviani, Simonetta ;

Pierri, Ivana ;

Levis, Alessandro .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (24) :3746-3752

← 1 2 3 4 5 →